Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib | Nasdaq
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Alan Auerbach: Puma Biotech's Overnight Billionaire - Forbes India
Vir Biotech IPO: What You Need To Know
DFAN14A
Puma Biotechnology Inc. (NYSE: PBYI) shareholders vote against PPD founder Fred Eshelman - Triangle Business Journal
Puma Biotechnology Inc. (PBYI) Stock Price, Quote & News | Stock Analysis
Puma Biotech to pay PPD founder $22M in defamation suit from proxy fight | Fierce Pharma
Puma Biotechnology Inc. (NYSE: PBYI) shareholders vote against PPD founder Fred Eshelman - Triangle Business Journal
Puma Biotechnology, Inc. | LinkedIn
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
Puma Wins 5-Year Extension of Patent on Main Breast Cancer Treatment Drug Nerlynx - Los Angeles Business Journal
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
PUMA_BIOTECHNOLOGY
From summer lull to biotech's record-breaking month | Evaluate
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Inc. (PBYI) Stock Price, Quote & News | Stock Analysis
Breakeven On The Horizon For Puma Biotechnology, Inc. (NASDAQ:PBYI) | Nasdaq
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotech's Nerlynx Included In NCCN Guidelines For Breast Cancer - Puma Biotechnology (NASDAQ:PBYI) - Benzinga
Puma Biotechnology, Inc.: Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
